AbbVie wraps up $64M oncology, immunology deal with Tentarix

AbbVie is wrapping its tentacles around a few more oncology and immunology candidates thanks to a new $64 million deal with Tentarix Biotherapeutics.

The announcement was low on detail, but the two have inked a multiyear collaboration to discover and develop biologics in the two disease areas using the biotech’s Tentacles platform. The company’s tech designs biologics that activate immune cells to modulate disease pathways while avoiding safety concerns typically associated with less specific immune cell targeting.